Year in review 2013: Critical Care - sepsis

Critical Care

Volumn 18, Issue 5, 2014, Pages

  de Montmollin, Etienne ^a   Annane, Djillali ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; HUMAN; INTENSIVE CARE; PROCEDURES; SEPSIS; TRENDS;

CLINICAL TRIALS AS TOPIC; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; SEPSIS;

EID: 84908068701     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0578-x     Document Type: Review

References (53)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent J-L, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625.
2. Achouiti A, van der Meer AJ, Florquin S, Yang H, Tracey KJ, van't Veer C, de Vos AF, van der Poll T. High-mobility group box 1 and the receptor for advanced glycation end products contribute to lung injury during Staphylococcus aureus pneumonia. Crit Care 2013, 17:R296. 10.1186/cc13162, 24342460.
3. Narvaez-Rivera RM, Rendon A, Salinas-Carmona MC, Rosas-Taraco AG. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. BMC Infect Dis 2012, 12:15. 10.1186/1471-2334-12-15, 22264245.
4. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003, 4:670-679. 10.1038/ni944, 12796776.
5. Shubin NJ, Monaghan SF, Heffernan DS, Chung C-S, Ayala A: B and T lymphocyte attenuator expression on CD4+T-cells associates with sepsis and subsequent infections in ICU patients.Crit Care 2013, 17:R276..
6. Devaney J, Curley GF, Hayes M, Masterson C, Ansari B, O'Brien T, O'Toole D, Laffey JG. Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Crit Care 2013, 17:R82. 10.1186/cc12696, 23622108.
7. Monserrat J, de Pablo R, Diaz-Martín D, Rodríguez-Zapata M, de la Hera A, Prieto A, Alvarez-Mon M. Early alterations of B cells in patients with septic shock. Crit Care 2013, 17:R105. 10.1186/cc12750, 23721745.
8. Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care 2013, 17:R10. 10.1186/cc11934, 23327349.
9. Sjövall F, Morota S, Persson J, Hansson MJ, Elmér E. Patients with sepsis exhibit increased mitochondrial respiratory capacity in peripheral blood immune cells. Crit Care 2013, 17:R152. 10.1186/cc12831, 23883738.
10. Toufekoula C, Papadakis V, Tsaganos T, Routsi C, Orfanos SE, Kotanidou A, Carrer D-P, Raftogiannis M, Baziaka F, Giamarellos-Bourboulis EJ. Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant gram-negative bacteria: experimental and clinical evidence. Crit Care 2013, 17:R6. 10.1186/cc11930, 23324310.
11. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595. 10.1056/NEJMra002709, 11529214.
12. Mederle K, Schweda F, Kattler V, Doblinger E, Miyata K, Höcherl K, Oike Y, Castrop H. The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension. Crit Care 2013, 17:R130. 10.1186/cc12809, 23844607.
13. Sharawy N. Vasoplegia in septic shock: do we really fight the right enemy?. J Crit Care 2014, 29:83-87. 10.1016/j.jcrc.2013.08.021, 24095623.
14. Vassiliou AG, Maniatis NA, Orfanos SE, Mastora Z, Jahaj E, Paparountas T, Armaganidis A, Roussos C, Aidinis V, Kotanidou A. Induced expression and functional effects of aquaporin-1 in human leukocytes in sepsis. Crit Care 2013, 17:R199. 10.1186/cc12893, 24028651.
15. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 2014, 20:30-34. 10.1016/j.jiac.2013.07.005, 24462421.
16. Liu B, Chen Y-X, Yin Q, Zhao Y-Z, Li C-S. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit Care 2013, 17:R244. 10.1186/cc13070, 24138799.
17. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, Morello F, Lupia E, Moiraghi C, Mengozzi G, Battista S. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013, 17:R168. 10.1186/cc12847, 23899120.
18. Lin W-C, Lu S-L, Lin C-F, Chen C-W, Chao L, Chao J, Lin Y-S. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care 2013, 17:R27. 10.1186/cc12507, 23394256.
19. Li P, Bledsoe G, Yang Z-R, Fan H, Chao L, Chao J. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 2014, 142:216-226. 10.1111/imm.12242, 24467264.
20. Llewelyn MJ, Berger M, Gregory M, Ramaiah R, Taylor AL, Curdt I, Lajaunias F, Graf R, Blincko SJ, Drage S, Cohen J. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care 2013, 17:R60. 10.1186/cc12588, 23531337.
21. Matera G, Puccio R, Giancotti A, Quirino A, Pulicari MC, Zicca E, Caroleo S, Renzulli A, Liberto MC, Focà A. Impact of interleukin-10, soluble CD25 and interferon-γ on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. Crit Care 2013, 17:R64. 10.1186/cc12596, 23561467.
22. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013, 17:R115. 10.1186/cc12787, 23787145.
23. Pachot A, Monneret G, Brion A, Venet F, Bohé J, Bienvenu J, Mougin B, Lepape A. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005, 33:31-38. discussion 236-237, 10.1097/01.CCM.0000150958.20209.A3, 15644645.
24. Cajander S, Bäckman A, Tina E, Strålin K, Söderquist B, Källman J. Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis. Crit Care 2013, 17:R223. 10.1186/cc13046, 24093602.
25. Giamarellos-Bourboulis EJ, Apostolidou E, Lada M, Perdios I, Gatselis NK, Tsangaris I, Georgitsi M, Bristianou M, Kanni T, Sereti K, Kyprianou MA, Kotanidou A, Armaganidis A. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care 2013, 17:R247. 10.1186/cc13073, 24144038.
26. Toth I, Mikor A, Leiner T, Molnar Z, Bogar L, Szakmany T. Effects of IgM-enriched immunoglobulin therapy in septic-shock-induced multiple organ failure: pilot study. J Anesth 2013, 27:618-622. 10.1007/s00540-012-1553-9, 23314695.
27. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles WC. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011, 39:702-710. 10.1097/CCM.0b013e318206d285, 21242795.
28. Luz Fiusa MM, Costa-Lima C, de Souza GR, Vigorito AC, Penteado Aranha FJ, Lorand-Metze I, Annichino-Bizzacchi JM, de Souza CA, De Paula EV. A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care 2013, 17:R169. 10.1186/cc12848, 23915833.
29. De Backer D, Orbegozo Cortes D, Donadello K, Vincent J-L. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence 2014, 5:73-79. 10.4161/viru.26482, 24067428.
30. Kim CH, Park JT, Kim EJ, Han JH, Han JS, Choi JY, Han SH, Yoo T-H, Kim YS, Kang S-W, Oh HJ. An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. Crit Care 2013, 17:R282. 10.1186/cc13145, 24321201.
31. Sadaka F, O'Brien J, Prakash S. Red cell distribution width and outcome in patients with septic shock. J Intensive Care Med 2013, 28:307-313. 10.1177/0885066612452838, 22809690.
32. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631. 16521260.
33. Gando S, Saitoh D, Ogura H, Fujishima S, Mayumi T, Araki T, Ikeda H, Kotani J, Kushimoto S, Miki Y, Shiraishi S-I, Suzuki K, Suzuki Y, Takeyama N, Takuma K, Tsuruta R, Yamaguchi Y, Yamashita N, Aikawa N. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 2013, 17:R111. 10.1186/cc12783, 23787004.
34. Drewry AM, Fuller BM, Bailey TC, Hotchkiss RS. Body temperature patterns as a predictor of hospital-acquired sepsis in afebrile adult intensive care unit patients: a case-control study. Crit Care 2013, 17:R200. 10.1186/cc12894, 24028682.
35. Kushimoto S, Gando S, Saitoh D, Mayumi T, Ogura H, Fujishima S, Araki T, Ikeda H, Kotani J, Miki Y, Shiraishi S-I, Suzuki K, Suzuki Y, Takeyama N, Takuma K, Tsuruta R, Yamaguchi Y, Yamashita N, Aikawa N. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care 2013, 17:R271. 10.1186/cc13106, 24220071.
36. Lorente L, Martín MM, Abreu-González P, Domínguez-Rodriguez A, Labarta L, Díaz C, Solé-Violán J, Ferreres J, Cabrera J, Igeño JC, Jiménez A. Sustained high serum malondialdehyde levels are associated with severity and mortality in septic patients. Crit Care 2013, 17:R290. 10.1186/cc13155, 24326199.
37. Elkington PTG, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005, 142:12-20. 10.1111/j.1365-2249.2005.02840.x, 16178851.
38. Lorente L, Martín M, Plasencia F, Solé-Violán J, Blanquer J, Labarta L, Díaz C, Borreguero-León JM, Jiménez A, Páramo JA, Orbe J, Rodríguez JA, Salido E. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Crit Care 2013, 17:R94. 10.1186/cc12739, 23706069.
39. Chang KC, Burnham C-A, Compton SM, Rasche DP, Mazuski R, SMcDonough J, Unsinger J, Korman AJ, Green JM, Hotchkiss RS. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013, 17:R85. 10.1186/cc12711, 23663657.
40. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, Robbins P, Ulbrandt N, Suzich J, Green J, Patera AC, Blair W, Krishnan S, Hotchkiss R. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014, 18:R3. 10.1186/cc13176, 24387680.
41. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007, 14:431-441. 10.1016/j.chembiol.2007.03.007, 17462578.
42. Wang W, Zhao F, Fang Y, Li X, Shen L, Cao T, Zhu H. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care 2013, 17:R44. 10.1186/cc12558, 23497622.
43. Gutsmann T, Razquin-Olazarán I, Kowalski I, Kaconis Y, Howe J, Bartels R, Hornef M, Schürholz T, Rössle M, Sanchez-Gómez S, Moriyon I, Martinez de Tejada G, Brandenburg K. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010, 54:3817-3824. 10.1128/AAC.00534-10, 20606063.
44. Schuerholz T, Doemming S, Hornef M, Martin L, Simon T-P, Heinbockel L, Brandenburg K, Marx G. The anti-inflammatory effect of the synthetic antimicrobial peptide 19-2.5 in a murine sepsis model: a prospective randomized study. Crit Care 2013, 17:R3. 10.1186/cc11920, 23302299.
45. Rimmelé T, Kaynar AM, McLaughlin JN, Bishop JV, Fedorchak MV, Chuasuwan A, Peng Z, Singbartl K, Frederick DR, Zhu L, Carter M, Federspiel WJ, Zeevi A, Kellum JA. Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study. Crit Care 2013, 17:R59. 10.1186/cc12587, 23531333.
46. Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E, Puccetti P. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 2007, 1112:326-338. 10.1196/annals.1415.002, 17495242.
47. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013, 17:R8. 10.1186/cc11932, 23327199.
48. Investigators PCESS, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014, 370:1683-1693. 10.1056/NEJMoa1401602.
49. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014, 311:1308-1316. 10.1001/jama.2014.2637, 24638143.
50. Cuthbertson BH, Elders A, Hall S, Taylor J, Maclennan G, Mackirdy F, Mackenzie SJ. Mortality and quality of life in the five years after severe sepsis. Crit Care 2013, 17:R70. 10.1186/cc12616, 23587132.
51. Schmidt K, Thiel P, Mueller F, Schmuecker K, Worrack S, Mehlhorn J, Engel C, Brenk-Franz K, Kausche S, Jakobi U, Bindara-Klippel A, Schneider N, Freytag A, Davydow D, Wensing M, Brunkhorst FM, Gensichen J. Sepsis survivors monitoring and coordination in outpatient health care (SMOOTH): study protocol for a randomized controlled trial. Trials 2014, 15:283. 10.1186/1745-6215-15-283, 25015838.
52. Phua J, Ngerng WJ, See KC, Tay CK, Kiong T, Lim HF, Chew MY, Yip HS, Tan A, Khalizah HJ, Capistrano R, Lee KH, Mukhopadhyay A. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. Crit Care 2013, 17:R202. 10.1186/cc12896, 24028771.
53. Sakr Y, Elia C, Mascia L, Barberis B, Cardellino S, Livigni S, Fiore G, Filippini C, Ranieri VM. The influence of gender on the epidemiology of and outcome from severe sepsis. Crit Care 2013, 17:R50. 10.1186/cc12570, 23506971.